Combining trametinib and navitoclax to treat recurrent ovarian cancer
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma
This study is testing a new combination treatment for women with recurrent ovarian cancer that hasn't responded to standard therapies, aiming to see if it can help improve their outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10895326 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for recurrent ovarian cancer, particularly focusing on high grade serous carcinoma, which often becomes resistant to standard therapies. The study aims to evaluate the effectiveness of a combination therapy that targets specific cancer pathways and proteins involved in cell survival. By using trametinib, which inhibits the MEK protein in the Ras-ERK pathway, alongside navitoclax, which targets anti-apoptotic proteins BCL2 and BCLXL, the research seeks to improve treatment outcomes for patients with resistant forms of ovarian cancer. Patients may be monitored for their response to this innovative therapy through clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent ovarian cancer, particularly those with high grade serous carcinoma or other subtypes that exhibit resistance to platinum-based therapies.
Not a fit: Patients with early-stage ovarian cancer or those who have not experienced treatment resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with recurrent ovarian cancer who have limited responses to existing therapies.
How similar studies have performed: Previous studies have shown promising results with similar combination therapies targeting the Ras-ERK pathway and anti-apoptotic proteins, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Matulonis, Ursula Anne — Dana-Farber Cancer Inst
- Study coordinator: Matulonis, Ursula Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.